<DOC>
	<DOCNO>NCT00263068</DOCNO>
	<brief_summary>This multicenter , open-label trial ass safety tolerability rotigotine ( SPM 936 ) subject idiopathic Restless Legs Syndrome ( RLS ) , administer optimal dose 1 year . Subjects successfully complete Maintenance Period Taper Period SP792 allow enroll trial . All subject begin Titration Period daily dosage 1.125mg rotigotine ( 2.5cm2 patch ) . Subjects up-titrated 7-day interval 1.125mg ( 2.5cm2 increment , initial titration step ) 2.25mg interval ( 5cm2 ) increment maximum dose 6.75mg/day ( 15cm2 ) rotigotine . The maximum length titration 28 day ( Â±3 day ) , although subject require 28 day reach optimal dose . A subject 's dose may increase decrease , need investigator maintain subject 's effective dose Maintenance Period . A Taper Period provide allow safe , gradual withdrawal trial medication</brief_summary>
	<brief_title>An Extension Trial Investigate Long-Term Treatment With Transdermal Rotigotine Idiopathic Restless Legs Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Idiopathic restless legs syndrome Subject ongoing serious adverse event SP792 assess related trial medication investigator and/or sponsor . Subject pregnant , nursing , woman childbearing potential surgically sterile , 2 year postmenopausal , consistently use 2 combined effective method contraception , include least 1 barrier method , unless sexually abstinent . Subject medical psychiatric condition , opinion investigator , jeopardize would compromise subject 's ability participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>IDIOPATHIC RESTLESS LEGS SYNDROME</keyword>
</DOC>